Based on promising preclinical data in breast and multiple other cancer types, DR4 and DR5 agonists have been developed for clinical use over the past two decades, and, as outlined below, trials of single agent TRAIL death receptor agonists and combinations have been largely disappointing. Here, TNFRSF10A is linked to cancer.